Edition:
United Kingdom

Nabriva Therapeutics PLC (NBRV.OQ)

NBRV.OQ on NASDAQ Stock Exchange Global Select Market

5.83USD
8 Dec 2017
Change (% chg)

-- (--)
Prev Close
$5.83
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
151,111
52-wk High
$14.09
52-wk Low
$4.31

Select another date:

Thu, Nov 9 2017

BRIEF-Nabriva Therapeutics reports Q3 loss per share $0.79

* Nabriva Therapeutics reports third quarter 2017 financial results and recent corporate highlights

BRIEF-Nabriva Therapeutics announces pricing of public offering of ordinary shares of nearly $80 mln

* Nabriva Therapeutics announces pricing of public offering of ordinary shares of approximately $80 million

Nabriva's pneumonia drug succeeds in late-stage trial, shares soar

Nabriva Therapeutics Plc shares nearly doubled in morning trading on Monday after the company said its experimental antibiotic for community-acquired bacterial pneumonia (CABP) met the main goal of a late-stage study.

UPDATE 2-Nabriva's pneumonia drug succeeds in late-stage trial, shares soar

Sept 18 Nabriva Therapeutics Plc shares nearly doubled in morning trading on Monday after the company said its experimental antibiotic for community-acquired bacterial pneumonia (CABP) met the main goal of a late-stage study.

Nabriva's pneumonia drug meets main goal in late-stage study

Sept 18 Nabriva Therapeutics Plc said on Monday its experimental treatment for community-acquired bacterial pneumonia met the main goal in a late-stage study, sending its shares up more than 70 percent in premarket trading.

BRIEF-Nabriva therapeutics announces positive topline results

* Nabriva Therapeutics announces positive topline results from global, phase 3 clinical trial evaluating IV and oral lefamulin for the treatment of community-acquired bacterial pneumonia

BRIEF-Nabriva Therapeutics reports Q2 loss per share $0.54

* Nabriva Therapeutics reports second quarter 2017 financial results and recent corporate highlights

BRIEF-Nabriva Therapeutics files for mixed shelf of upto $175 mln - SEC Filing

* Files for mixed shelf of upto $175 million - SEC Filing Source text: [http://bit.ly/2v5i1V5] Further company coverage:

BRIEF-Nabriva Therapeutics appoints new board members

* Nabriva Therapeutics appoints Carrie Bourdow and Colin Broom to the board Source text for Eikon: Further company coverage:

Select another date: